Featured Research

from universities, journals, and other organizations

Early Phase II Results Suggest Bosutinib Safe, Effective For CML

Date:
December 11, 2007
Source:
University of Texas M. D. Anderson Cancer Center
Summary:
A new drug for chronic myelogenous leukemia works for patients who have developed resistance to frontline therapy and causes fewer side effects than other medications in its class, scientists report.

A new drug for chronic myelogenous leukemia works for patients who have developed resistance to frontline therapy and causes fewer side effects than other medications in its class, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reports at the 49th annual meeting of the American Society of Hematology.

Related Articles


"Bosutinib has shown good efficacy and very little toxicity compared to other tyrosine kinase inhibitors at this stage of the clinical trial," says lead researcher Jorge Cortes, M.D., professor in M. D. Anderson's Department of Leukemia.

Bosutinib, developed by Wyeth Pharmaceuticals, is being tested in patients in the early or chronic phase of CML whose disease has become resistant to imatinib or who have become intolerant of imatinib's side effects.

So far, 98 patients have enrolled in the relatively new clinical trial, with median duration of treatment at 5.1 months.

Among 23 evaluable patients who had become resistant to imatinib, 17 (74 percent) achieved a complete hematological response - normal blood counts. Of 36 evaluable for cytogenetic response - reduction of the abnormal chromosome that causes the disease - 15 had a major response and 12 of those had a complete response, or absence, of the chromosome.

"These responses are comparable to other drugs at a similar stage of follow-up," Cortes says.

Interestingly, a small number of patients who had also become resistant to second-line treatments nilotinib and dasatinib derived some benefit from taking the new drug. Out of eight such patients, three achieved complete hematologic response and two achieved major cytogenetic response.

The most common side effects were low-grade nausea, vomiting and diarrhea, which improved greatly three or four weeks into therapy. Higher grade side effects such as low counts of platelets, white or red blood cells ranged from 1 to 9 percent of patients. Fluid build-up in the lungs and other organs occurred in only 12 patients and was of low grade.

Cortes says the researchers suspect that the low grade and frequency of side effects is probably a result of the drug's specificity in the proteins that it targets. Bosutinib inhibits SRC and ABL proteins but does not affect platelet derived growth factor receptor or C-Kit, two similar kinases that are affected by other CML drugs.

CML is caused by the Bcr-Abl protein, which results from a chromosomal abnormality called the Philadelphia Chromosome. Bcr-Abl is a tyrosine kinase that fuels an overabundance of white blood cells and immature stem cells called blasts that crowd out red blood cells and platelets.

Tyrosine kinases are a specialized subgroup of protein kinases, which regulate protein behavior by attaching phosphate groups to proteins or small molecules. Bosutinib, like imatinib (Gleevec(r)), dasatinib (Sprycel(r)) and nilotinib (Tasigna(r)), is a tyrosine kinase inhibitor.

The researchers also found that bosutinib is effective against a variety of Bcr-Abl mutants that cause CML and conclude that the drug is effective in imatinib-resistant patients with chronic CML across a range of mutations and after the failure of other tyrosine kinase inhibitors.

Co-authors with Cortes are Hagop Kantarjian, M.D., of M. D. Anderson's Department of Leukemia; Tim Bruemmendorf, M.D., University of Hamburg; H. Jean Khoury, M.D., and Becker Hewes, M.D. of Emory University; Gianantonio Rosti, University of Bologna, Italy; Thomas Fischer, M.D., Johannes Gutenberg University, Mainz, Germany; L. Tornaghi; E.C. Martin of Wyeth Research; and Carlo Gambacorti-Passerini, M.D., and Lucia Tornaghi, both of University of Milano-Bicocca.


Story Source:

The above story is based on materials provided by University of Texas M. D. Anderson Cancer Center. Note: Materials may be edited for content and length.


Cite This Page:

University of Texas M. D. Anderson Cancer Center. "Early Phase II Results Suggest Bosutinib Safe, Effective For CML." ScienceDaily. ScienceDaily, 11 December 2007. <www.sciencedaily.com/releases/2007/12/071211094921.htm>.
University of Texas M. D. Anderson Cancer Center. (2007, December 11). Early Phase II Results Suggest Bosutinib Safe, Effective For CML. ScienceDaily. Retrieved November 27, 2014 from www.sciencedaily.com/releases/2007/12/071211094921.htm
University of Texas M. D. Anderson Cancer Center. "Early Phase II Results Suggest Bosutinib Safe, Effective For CML." ScienceDaily. www.sciencedaily.com/releases/2007/12/071211094921.htm (accessed November 27, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, November 27, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com
Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) — Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) — Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins